Prot #1366-0031: A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel-group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults with Early Progressive Diffuse Cutaneous Systemic Sclerosis

Project: Research project

Project Details

StatusActive
Effective start/end date3/24/23 → 3/24/26

Funding

  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1366-0031)